About Bradmer Pharmaceuticals

A biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

About Pharma Finance 2007

A unique two-day intensive approach to find and to offer, in an international environment: AIC, Patents & Licensing, Co-Marketing of Bio-Nano-Pharma Technologies. Pharma Finance 2007 is not an arena-style conference. It is specifically designed to support in-depth partnership development.